Abstract
The present study reports a case of tazobactam and piperacillin (TZP)-induced thrombocytopenia in an elderly patient, from which complete clinical data and peripheral blood samples were collected. Platelet numbers were decreased 1 day following TZP treatment initiation; however, they were revealed to have increased 1–2 days following withdrawal of TZP, and had reached normal levels 3–5 days later. There was no evidence of bone marrow suppression, antibodies against peripheral plasma platelets were absent and levels of complement C3 were decreased. These results suggested that TZP was able to cause rapid and reversible thrombocytopenia, which was not associated with bone marrow suppression but may have involved activation of complement C3. The results of the present study therefore suggest that doctors should be aware of the risk of thrombocytopenia in patients treated with TZP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
